Antidepressants in Japan

The number of new psychiatric drugs, and especially antidepressants on the market in Japan, is significantly less than Western countries.[1]

One of the biggest barriers to antidepressants coming to the market is that the medical insurance system in Japan is national, and the authorities are keen to contain a potentially explosive market for drugs like antidepressants that could be used or abused by persons in various forms of distress.[2]

Although large epidemiological studies have not been done in Japan, it is thought that up to 6 million Japanese suffer from depression, with a lifetime prevalence of 13 to 17.3%, which is similar to that seen in Western countries.[2]

Market

While the market has seen the entry of the selective serotonin reuptake inhibitors (SSRIs) fluvoxamine (Luvox-Fujisawa, Depromel-Meiji Seika), paroxetine (Paxil-GSK), sertraline (Zoloft-Pfizer), and the SNRI milnacipran (Toledomin-Asahi Kasei-Janssen), other antidepressants including citalopram (Cipramil/Cipralex-Lundbeck), Celexa (Forest), fluoxetine (Prozac- Eli Lilly), venlafaxine (Effexor-Wyeth), mirtazapine (Remeron-Organon), and others are either still under investigation in Japan or have dropped their pursuit on gaining entry into the Japanese market.[3]

Although none of the antidepressants on the market in Japan have been studied using placebo controls, this had begun to change since the beginning of the 2000s. Prior clinical developments have pitted the new drug against a drug already on the market using a non-inferiority method of comparison, however, this method is known to be subject to placebo effects, e.g. depressive symptoms lifting due to effects other than pharmacologic drug effect.[2]

Sertraline (Pfizer) received approval in April 2006 after over 15 years of clinical trial development in Japan.[4] The Japan algorithm for mood disorders[5] does not include many of the post-tricyclic antidepressants used as first-line antidepressants in Western countries for almost two decades, and recent studies are still comparing SSRIs and tricyclic antidepressants, even though tricyclics are clearly 2nd or 3rd line treatments in the West.[6] Organon International and Meiji Seika have filed an application for approval of mirtazapine in Japan, a drug on the market in many Western countries since 1994.[7]

Citalopram (Lundbeck), an SSRI on the market since the late 1980s is not available in Japan, however on April 22, 2011 escitalopram (the S-isomer enantiomer of citalopram), was approved for use in Japan.[8] There is little news, however, on the status of bupropion (Glaxo Smith-Kline), used widely in Western countries since the early 1990s and long in clinical trials in Japan.

References

  1. ↑ Kanba S (Jan 1999). "Disparities in drug development: the Japanese paradox". J Psychiatry Neurosci 24 (1): 13–4. PMC 1188972. PMID 9987203.
  2. 1 2 3 Berger D (Sep 2005). "Antidepressant clinical development in Japan: Current perspectives and future horizons" (PDF). Clinical Research Focus 16 (7): 32–5.
  3. ↑ Berger D, Fukunishi I (Jul 1996). "Psychiatric drug development in Japan". Science 273 (5273): 318–9. doi:10.1126/science.273.5273.318. PMID 8685717.
  4. ↑ Life Sciences World - Online resource for biotechnology, pharmaceutical, medical devices and life sciences industries.
  5. ↑ Nomura S, Sawamura T, Kobayashi N, Yoshino A (Sep 2004). "Medication algorithm for mood disorders: Present status and future direction in Japan". International Journal of Psychiatry in Clinical Practice 8 (3): 139–45. doi:10.1080/13651500410005432.
  6. ↑ Otsubo T, Akimoto Y, Yamada H; et al. (Jan 2005). "A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression". Pharmacopsychiatry 38 (1): 30–5. doi:10.1055/s-2005-837769. PMID 15706464.
  7. ↑ Antidepressant Mirtazapine (Remeron) Submitted For Approval In Japan.
  8. ↑ Fraende, Mette (April 22, 2011). "Lundbeck gets Lexapro approval in Japan". Reuters.

External links

This article is issued from Wikipedia - version of the Wednesday, April 29, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.